Annovis Bio, Inc. (ANVS) has a consensus analyst rating of Buy, based on 8 analysts covering the stock. Of those, 6 recommend buying, 2 recommend holding, and 0 recommend selling.
The analyst consensus price target for ANVS is $25.67, representing a +1,358.5% upside from the current price of $1.76. Price targets range from a low of $21.00 to a high of $30.00.
